BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khan AR, Wei X, Xu X. Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides. J Hepatocell Carcinoma 2021;8:1089-115. [PMID: 34522691 DOI: 10.2147/JHC.S318070] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Feng Y, Zhang H, Ren Q, Li C, Liu S, Zheng C, Xia X. Contrast-enhanced CT parameters predict short-term tumor response in patients with hepatocellular carcinoma who received sequential combined anti-angiogenesis and immune checkpoint inhibitor treatment. Eur J Radiol 2023;162:110784. [PMID: 36958125 DOI: 10.1016/j.ejrad.2023.110784] [Reference Citation Analysis]
2 Zou X, Xu Q, You R, Yin G. Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Adv Ther 2023. [PMID: 36805422 DOI: 10.1007/s12325-023-02449-6] [Reference Citation Analysis]
3 Xu Q, Zeng J, Zeng J, Huang Y, Guo P, Lan L. The effect of Microvascular Invasion on Hepatocellular Carcinoma with Portal Vein Tumor Thrombus after Hepatectomy: A multicenter study.. [DOI: 10.21203/rs.3.rs-2523854/v1] [Reference Citation Analysis]
4 Lee CH. Portal vein thrombosis on unenhanced MRI: a case series. BJR Case Rep 2023;9:20220059. [PMID: 36873239 DOI: 10.1259/bjrcr.20220059] [Reference Citation Analysis]
5 Li S, Wu J, Wu J, Fu Y, Zeng Z, Li Y, Li H, Liao W, Yan M. Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study. Front Immunol 2023;14:1109771. [PMID: 36875116 DOI: 10.3389/fimmu.2023.1109771] [Reference Citation Analysis]
6 Zhang JX, Yan HT, Ding Y, Liu J, Liu S, Zu QQ, Shi HB. Low Psoas-Muscle index is associated with decreased survival in hepatocellular carcinoma treated with transarterial chemoembolization. Ann Med 2022;54:1562-9. [PMID: 35639492 DOI: 10.1080/07853890.2022.2081872] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Awiwi MO, Elsayes KM, Mohamed YI, Altameemi L, Gjoni M, Irshad OM, Sayed Ahmed A, Kaseb AO, Salem U. . JHC 2022;Volume 9:913-27. [DOI: 10.2147/jhc.s379428] [Reference Citation Analysis]
8 Srivastava A, Parambath HK, Ramdulari AV, Saxena H, Kumar R, Pandey S, Shalimar, Gupta S, Jee B. Is hepatocellular carcinoma complicated with portal vein tumor thrombosis potentially curable by radiotherapy in the form of stereotactic body radiation therapy? Int J Radiat Biol 2022;:1-15. [PMID: 35311612 DOI: 10.1080/09553002.2022.2055800] [Reference Citation Analysis]
9 Liu J, Yang C, Huang XM, Lv PP, Yang YK, Zhao JN, Zhao SY, Sun WJ. Knockdown of FBI-1 Inhibits the Warburg Effect and Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeted Agents via miR-3692/HIF-1α. Front Oncol 2021;11:796839. [PMID: 34869045 DOI: 10.3389/fonc.2021.796839] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
10 Kobayashi M, Wada H, Fukui S, Mizutani H, Ichikawa Y, Shiraki K, Moritani I, Inoue H, Shimaoka M, Shimpo H. A Clot Waveform Analysis Showing a Hypercoagulable State in Patients with Malignant Neoplasms. J Clin Med 2021;10:5352. [PMID: 34830633 DOI: 10.3390/jcm10225352] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]